Literature DB >> 20417118

In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization.

Noboru Maeda1, Keigo Osuga, Hiroki Higashihara, Koji Mikami, Kaname Tomoda, Shinichi Hori, Tetsuro Nakazawa, Hironobu Nakamura.   

Abstract

PURPOSE: To find appropriate contrast media to load cisplatin into superabsorbent polymer (SAP) and to analyze the absorption and elution kinetics of cisplatin to and from SAP.
MATERIALS AND METHODS: Three contrast media-ioxaglic acid 320 mg/mL, iohexol 300 mg/mL, and iopamidol 300 mg/mL-were tested for solubility of a new highly soluble cisplatin powder. The appropriate concentrations of cisplatin were predetermined according to the solubility in each contrast medium. For each concentration, we assessed the cisplatin elution kinetics with an atomic absorption spectrophotometer. The SAP particle diameters (106-150 microm dry size) before and after drug elution were also measured.
RESULTS: The concentrations of cisplatin were predetermined as 2.5 mg/mL in ioxaglic acid, 2.5 mg/mL in iohexol, and 5.0 mg/mL in iohexol. At these concentrations, 100 mg of SAP carried 5 mg, 25 mg, and 50 mg of cisplatin dissolved in ioxaglic acid (2.5 mg/mL) and iohexol (2.5 mg/mL and 5.0 mg/mL), respectively. Cisplatin-loaded SAP in ioxaglic acid and iohexol exhibited similar elution profiles, with cisplatin fractions of 15%, 40%, 70%, and 95% at 1, 3, 6, and 24 hours, respectively. By drug elution, the mean particle diameter changed from 0.31 mm to 0.61 mm in ioxaglic acid (2.5 mg/mL), from 0.54 mm to 0.60 mm in iohexol 2.5 mg/mL, and from 0.63 mm to 0.59 mm in iohexol 5.0 mg/mL.
CONCLUSIONS: SAP was confirmed to absorb and elute cisplatin within 24 hours. When mixed with iohexol, SAP carried a ten times larger dose of cisplatin and expanded twice as large as when mixed with ioxaglic acid. Cisplatin-loaded SAP may have potential as a drug delivery system for the clinical treatment of liver tumors. Copyright (c) 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417118     DOI: 10.1016/j.jvir.2010.02.009

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

Review 1.  Chemoembolization of hepatocellular carcinoma with HepaSphere™.

Authors:  Katerina Malagari; Anastasia Pomoni; Dimitrios Filippiadis; Dimitrios Kelekis
Journal:  Hepat Oncol       Date:  2015-05-05

Review 2.  Current status of embolic agents for liver tumor embolization.

Authors:  Keigo Osuga; Noboru Maeda; Hiroki Higashihara; Shinichi Hori; Tetsuro Nakazawa; Kaishu Tanaka; Masahisa Nakamura; Kentaro Kishimoto; Yusuke Ono; Noriyuki Tomiyama
Journal:  Int J Clin Oncol       Date:  2012-07-18       Impact factor: 3.402

Review 3.  Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope.

Authors:  Md Mohosin Rana; Marites P Melancon
Journal:  Biomimetics (Basel)       Date:  2022-06-10

4.  What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.

Authors:  Yusuke Kawamura; Kenji Ikeda; Taito Fukushima; Yuya Seko; Tasuku Hara; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Gut Liver       Date:  2013-08-14       Impact factor: 4.519

5.  Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.

Authors:  Shilong Han; Xiaoping Zhang; Liling Zou; Chenhui Lu; Jun Zhang; Jue Li; Maoquan Li
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.